The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma

[1]  S. Fox,et al.  The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma , 2020, npj Breast Cancer.

[2]  O. Mariani,et al.  The Genomic Landscape of Mucinous Breast Cancer. , 2019, Journal of the National Cancer Institute.

[3]  E. Morris,et al.  Correction to: Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions) , 2019, Breast Cancer Research and Treatment.

[4]  Kylie L. Gorringe,et al.  Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma , 2019, The Journal of pathology.

[5]  D. Karamchandani,et al.  Excision recommended in high‐risk patients: Revisiting the diagnosis of papilloma on core biopsy in the context of patient risk , 2019, The breast journal.

[6]  E. Morris,et al.  Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions) , 2018, Breast Cancer Research and Treatment.

[7]  D. Karamchandani,et al.  Should we excise? Are there any clinical or histologic features that predict upgrade in papillomas, incidental or non-incidental? , 2018, Annals of diagnostic pathology.

[8]  S. Noguchi,et al.  Mutational Analysis of AKT1 and PIK3CA in Intraductal Papillomas of the Breast with Special Reference to Cellular Components. , 2018, The American journal of pathology.

[9]  Kylie L. Gorringe,et al.  Molecular analysis of PALB2‐associated breast cancers , 2018, The Journal of pathology.

[10]  H. Bear,et al.  Papillary lesions of the breast: To excise or observe? , 2018, The breast journal.

[11]  Min Kyoon Kim,et al.  Management of benign papilloma without atypia diagnosed at ultrasound-guided core needle biopsy: Scoring system for predicting malignancy. , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[12]  Kylie L. Gorringe,et al.  Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer , 2017, Modern Pathology.

[13]  Kylie L. Gorringe,et al.  Copy number analysis by low coverage whole genome sequencing using ultra low-input DNA from formalin-fixed paraffin embedded tumor tissue , 2016, Genome Medicine.

[14]  E. Morris,et al.  First International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions) , 2016, Breast Cancer Research and Treatment.

[15]  F. Cunningham,et al.  The Ensembl Variant Effect Predictor , 2016, Genome Biology.

[16]  Min Jung Kim,et al.  Asymptomatic Benign Papilloma Without Atypia Diagnosed at Ultrasonography-Guided 14-Gauge Core Needle Biopsy: Which Subgroup can be Managed by Observation? , 2016, Annals of Surgical Oncology.

[17]  James Y. Zou.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[18]  A. Viale,et al.  Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas. , 2015, Journal of the National Cancer Institute.

[19]  Kylie L. Gorringe,et al.  Copy number analysis of ductal carcinoma in situ with and without recurrence , 2015, Modern Pathology.

[20]  Masayuki Yoshida,et al.  Intraductal papillomas on core biopsy can be upgraded to malignancy on subsequent excisional biopsy regardless of the presence of atypical features , 2015, Pathology international.

[21]  Serafim Batzoglou,et al.  Cell-lineage heterogeneity and driver mutation recurrence in pre-invasive breast neoplasia , 2015, Genome Medicine.

[22]  Jos Jonkers,et al.  CopywriteR: DNA copy number detection from off-target sequence data , 2015, Genome Biology.

[23]  Pieter Wesseling,et al.  DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly , 2014, Genome research.

[24]  G. McVean,et al.  Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications , 2014, Nature Genetics.

[25]  Julie C. Sapp,et al.  Clinical Delineation and Natural History of the PIK3CA-Related Overgrowth Spectrum** , 2014, American journal of medical genetics. Part A.

[26]  Q. Hu,et al.  Intracystic papillary carcinoma of breast: interrelationship with in situ and invasive carcinoma and a proposal of pathogenesis: array comparative genomic hybridization study of 14 cases , 2014, Modern Pathology.

[27]  N. Sneige,et al.  Benign papillomas without atypia diagnosed on core needle biopsy: experience from a single institution and proposed criteria for excision. , 2013, Clinical breast cancer.

[28]  Mauricio O. Carneiro,et al.  From FastQ Data to High‐Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline , 2013, Current protocols in bioinformatics.

[29]  Heng Li.  Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM , 2013, 1303.3997.

[30]  Jiri Bartek,et al.  Replication stress links structural and numerical cancer chromosomal instability , 2013, Nature.

[31]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..

[32]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[33]  L. Wilke,et al.  Risk of Invasive Breast Cancer and Ductal Carcinoma In Situ in Women with Atypical Papillary Lesions of the Breast , 2012, The breast journal.

[34]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[35]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[36]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[37]  Tatiana Popova,et al.  Supplementary Methods , 2012, Acta Neuropsychiatrica.

[38]  Sunil R. Lakhani,et al.  WHO classification of tumours of the breast , 2012 .

[39]  W. Cheng,et al.  Nonmalignant Breast Papillary Lesions at Core-Needle Biopsy: A Meta-analysis of Underestimation and Influencing Factors , 2012, Annals of Surgical Oncology.

[40]  Samantha E. Boyle,et al.  Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma , 2012, Breast Cancer Research and Treatment.

[41]  T. Nagayasu,et al.  Intracystic Papillary Carcinoma of Breast Harbors Significant Genomic Alteration Compared with Intracystic Papilloma: Genome‐wide Copy Number and LOH Analysis Using High‐Density Single‐Nucleotide Polymorphism Microarrays , 2011, The breast journal.

[42]  Vilppu J Tuominen,et al.  ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67 , 2010, Breast Cancer Research.

[43]  K. Byth,et al.  Diagnostic evaluation of papillary lesions of the breast on core biopsy , 2010, Modern Pathology.

[44]  Janice Patterson,et al.  High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast , 2010, Modern Pathology.

[45]  Malcolm Buchanan,et al.  Benign Papilloma on Core Biopsy Requires Surgical Excision , 2008, Annals of surgical oncology.

[46]  Emmanuel Barillot,et al.  High-resolution mapping of DNA breakpoints to define true recurrences among ipsilateral breast cancers. , 2008, Journal of the National Cancer Institute.

[47]  L. Collins,et al.  Papillary lesions of the breast: selected diagnostic and management issues , 2007, Histopathology.

[48]  Matthew Eckert,et al.  Breast Papillomas in the Era of Percutaneous Needle Biopsy , 2007, Annals of Surgical Oncology.

[49]  L. Jackson,et al.  Multiple papillomas of the breast: is current management adequate? , 2006, Breast.

[50]  G. Bevilacqua,et al.  Papillary lesions of the breast: a molecular progression? , 2005, Breast Cancer Research and Treatment.

[51]  P. V. van Diest,et al.  Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high‐molecular‐weight cytokeratin expression patterns , 2001, The Journal of pathology.

[52]  H. Koyama,et al.  Diagnosis of ductal carcinoma in situ (DCIS) and intraductal papilloma using fluorescence in Situ Hybridization (FISH) analysis , 2000, Breast cancer.

[53]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  S. Hirohashi,et al.  Detection of numerical alterations of chromosomes 3, 7, 17 and X in low-grade intracystic papillary tumors of the breast by multi-color fluorescencein situ hybridization , 1997, Breast cancer.

[55]  S. Hirohashi,et al.  Detection of numerical and structural alterations and fusion of chromosomes 16 and 1 in low-grade papillary breast carcinoma by fluorescence in situ hybridization. , 1997, The American journal of pathology.

[56]  W. Dupont,et al.  Subsequent breast carcinoma risk after biopsy with atypia in a breast papilloma , 1996, Cancer.

[57]  S. Hirohashi,et al.  Different Incidence of Loss of Heterozygosity on Chromosome 16q between Intraductal Papilloma and Intracystic Papillary Carcinoma of the Breast , 1994, Japanese journal of cancer research : Gann.

[58]  H. Bartsch,et al.  International Agency for Research on Cancer. , 1969, WHO chronicle.

[59]  A. Stout,et al.  THE PAPILLARY NEOPLASMS OF THE BREAST. I. BENIGN INTRADUCTAL PAPILLOMA , 1951, Annals of surgery.